RADNOR, Pa., April 2, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced today that its lead defensin-mimetic antibiotic, PMX-30063, has shown activity against 1,000 worldwide strains of Gram-positive staphylococci and streptococci clinical isolates, including strains resistant to linezolid, daptomycin, and methicillin. The data were presented at the 21st Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in London, United Kingdom. The presentation is available on PolyMedix's website at www.Polymedix.com.
